List of Contents

Pharmaceutical Manufacturing Market Size, Share, and Trends 2024 to 2034

The global pharmaceutical manufacturing market size was USD 576.54 billion in 2024, calculated at USD 649.76 billion in 2024 and is projected to surpass around USD 1,905.76 billion by 2034, expanding at a CAGR of 12.7% from 2024 to 2034. The North America pharmaceutical manufacturing market size was estimated at USD 184.49 billion in 2024 and is expected to grow at a fastest CAGR of 12.88% during the forecast year.

  • Last Updated : April 2024
  • Report Code : 1191
  • Category : Healthcare

Chapter 1. Introduction

1.1. Research Objective
1.2. Scope of the Study
1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach
2.2. Data Sources
2.3. Assumptions& Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Pharmaceutical Manufacturing Market Variables and Scope

4.1. Introduction
4.2. Market Classification and Scope

Chapter 5. COVID 19 Impact on Pharmaceutical Manufacturing Market

5.1. Covid-19: Pharmaceutical Manufacturing Industry Impact
5.2. Pharmaceutical Manufacturing Business Impact Assessment: Covid-19
5.2.1. Services Challenges/Disruption
5.2.2. Market Trends and Pharmaceutical Manufacturing Opportunities in the COVID-19 Landscape for Major Markets
5.3. Strategic Measures against Covid-19
5.3.1. Government Support and Initiative to Combat Covid-19
5.3.2. Proposal for Pharmaceutical Manufacturing Market Players to deal with Covid-19 Pandemic Scenario

6.1. Market Dynamics
6.1.1. Market Drivers
6.1.1.1. Increasing prevalence of chronic ailments
6.1.1.2. Growing geriatric population
6.1.2. Market Restraints
6.1.2.1. Stringent Regulations
6.1.3. Market Opportunities
6.1.3.1. Increasing prevalence of chronic ailments
6.1.3.2. Growing geriatric population

Chapter 7. Global Pharmaceutical Manufacturing Market: Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis
7.1.1.1. Pharmaceutical Manufacturing Market Revenue by Market Players
7.1.1.2. Pharmaceutical Manufacturing Market Revenue Market Share by Market Players
7.1.2. Key Organic/Inorganic Strategies Adopted by Players
7.1.2.1. Product Portfolio Expansion, Geographic Expansion, Drug Development Type Innovation
7.1.2.2. Merger and Acquisition, Collaboration and Partnerships
7.1.3. Market Players Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of End-users

Chapter 8. Global Pharmaceutical Manufacturing Market, By Drug Development Type

8.1. Pharmaceutical Manufacturing Market, by Drug Development Type
8.1.1. In-house
8.1.1.1. Market Revenue and Forecast
8.1.2. Outsource
8.1.2.1. Market Revenue and Forecast

Chapter 9. Global Pharmaceutical Manufacturing Market, By Route of Administration

9.1. Pharmaceutical Manufacturing Market, by Route of Administration
9.1.1. Topical
9.1.1.1. Market Revenue and Forecast
9.1.2. Oral
9.1.2.1. Market Revenue and Forecast
9.1.3. Inhalations
9.1.3.1. Market Revenue and Forecast
9.1.4. Parenteral
9.1.4.1. Market Revenue and Forecast
9.1.5. Others
9.1.5.1. Market Revenue and Forecast

Chapter 10. Global Pharmaceutical Manufacturing Market, By Formulation

10.1. Pharmaceutical Manufacturing Market, by Formulation
10.1.1. Injectable
10.1.1.1. Market Revenue and Forecast
10.1.2. Tablets
10.1.2.1. Market Revenue and Forecast
10.1.3. Suspensions
10.1.3.1. Market Revenue and Forecast
10.1.4. Capsules
10.1.4.1. Market Revenue and Forecast
10.1.5. Sprays
10.1.5.1. Market Revenue and Forecast
10.1.6. Others
10.1.6.1. Market Revenue and Forecast

Chapter 11. Global Pharmaceutical Manufacturing Market, By Therapy

11.1. Pharmaceutical Manufacturing Market, by Therapy
11.1.1. Diabetes
11.1.1.1. Market Revenue and Forecast
11.1.2. Cardiovascular Diseases
11.1.2.1. Market Revenue and Forecast
11.1.3. Respiratory Diseases
11.1.3.1. Market Revenue and Forecast
11.1.4. Cancer
11.1.4.1. Market Revenue and Forecast
11.1.5. Pain
11.1.5.1. Market Revenue and Forecast
11.1.6. Others
11.1.6.1. Market Revenue and Forecast

Chapter 12. Global Pharmaceutical Manufacturing Market, Regional Estimates and Trend Forecast

12.1. North America
12.1.1. Market Revenue Forecast by Drug Development Type
12.1.2. Market Revenue Forecast by Route of Administration
12.1.3. Market Revenue Forecast by Formulation
12.1.4. Market Revenue Forecast by Therapy
12.1.5. U.S
12.1.5.1. Market Revenue Forecast
12.1.6. Canada
12.1.6.1. Market Revenue Forecast
12.2. Europe
12.2.1. Market Revenue Forecast by Drug Development Type
12.2.2. Market Revenue Forecast by Route of Administration
12.2.3. Market Revenue Forecast by Formulation
12.2.4. Market Revenue Forecast by Therapy
12.2.5. UK
12.2.5.1. Market Revenue Forecast
12.2.6. Germany
12.2.6.1. Market Revenue Forecast
12.2.7. France
12.2.7.1. Market Revenue Forecast
12.2.8. Rest of EU
12.2.8.1. Market Revenue Forecast
12.3. Asia Pacific (APAC)
12.3.1. Market Revenue Forecast by Drug Development Type
12.3.2. Market Revenue Forecast by Route of Administration
12.3.3. Market Revenue Forecast by Formulation
12.3.4. Market Revenue Forecast by Therapy
12.3.5. China
12.3.5.1. Market Revenue Forecast
12.3.6. India
12.3.6.1. Market Revenue Forecast
12.3.7. Japan
12.3.7.1. Market Revenue Forecast
12.3.8. Rest of APAC
12.3.8.1. Market Revenue Forecast
12.4. LATAM
12.4.1. Market Revenue Forecast by Drug Development Type
12.4.2. Market Revenue Forecast by Route of Administration
12.4.3. Market Revenue Forecast by Formulation
12.4.4. Market Revenue Forecast by Therapy
12.4.5. Brazil
12.4.5.1. Market Revenue Forecast
12.4.6. Rest of LATAM
12.4.6.1. Market Revenue Forecast
12.5. Middle East and Africa (MEA)
12.5.1. Market Revenue Forecast by Drug Development Type
12.5.2. Market Revenue Forecast by Route of Administration
12.5.3. Market Revenue Forecast by Formulation
12.5.4. Market Revenue Forecast by Therapy
12.5.5. GCC
12.5.5.1. Market Revenue Forecast
12.5.6. North Africa
12.5.6.1. Market Revenue Forecast
12.5.7. South Africa
12.5.7.1. Market Revenue Forecast
12.5.8. Rest of MEA
12.5.8.1. Market Revenue Forecast

Chapter 13. Company Profiles

13.1. GlaxoSmithKline plc
13.1.1. Company Overview, Business Information, Regional Presence
13.1.2. Product Portfolio Analysis
13.1.2.1. Product Details, Specification, Formulation
13.1.3. Revenue, Price, and Gross Margin
13.1.4. Recent Developments and Strategies
13.2. Merck & Co., Inc.
13.2.1. Company Overview, Business Information, Regional Presence
13.2.2. Product Portfolio Analysis
13.2.2.1. Product Details, Specification, Formulation
13.2.3. Revenue, Price, and Gross Margin
13.2.4. Recent Developments and Strategies
13.3. Eli Lilly and Company
13.3.1. Company Overview, Business Information, Regional Presence
13.3.2. Product Portfolio Analysis
13.3.2.1. Product Details, Specification, Formulation
13.3.3. Revenue, Price, and Gross Margin
13.3.4. Recent Developments and Strategies
13.4. Johnson & Johnson
13.4.1. Company Overview, Business Information, Regional Presence
13.4.2. Product Portfolio Analysis
13.4.2.1. Product Details, Specification, Formulation
13.4.3. Revenue, Price, and Gross Margin
13.4.4. Recent Developments and Strategies
13.5. F. Hoffmann-La Roche Ltd.
13.5.1. Company Overview, Business Information, Regional Presence
13.5.2. Product Portfolio Analysis
13.5.2.1. Product Details, Specification, Formulation
13.5.3. Revenue, Price, and Gross Margin
13.5.4. Recent Developments and Strategies
13.6. Lonza
13.6.1. Company Overview, Business Information, Regional Presence
13.6.2. Product Portfolio Analysis
13.6.2.1. Product Details, Specification, Formulation
13.6.3. Revenue, Price, and Gross Margin
13.6.4. Recent Developments and Strategies
13.7. Pfizer, Inc.
13.7.1. Company Overview, Business Information, Regional Presence
13.7.2. Product Portfolio Analysis
13.7.2.1. Product Details, Specification, Formulation
13.7.3. Revenue, Price, and Gross Margin
13.7.4. Recent Developments and Strategies
13.8. Sanofi SA
13.8.1. Company Overview, Business Information, Regional Presence
13.8.2. Product Portfolio Analysis
13.8.2.1. Product Details, Specification, Formulation
13.8.3. Revenue, Price, and Gross Margin
13.8.4. Recent Developments and Strategies
13.9. Novartis AG
13.9.1. Company Overview, Business Information, Regional Presence
13.9.2. Product Portfolio Analysis
13.9.2.1. Product Details, Specification, Formulation
13.9.3. Revenue, Price, and Gross Margin
13.9.4. Recent Developments and Strategies
13.10. AstraZeneca
13.10.1. Company Overview, Business Information, Regional Presence
13.10.2. Product Portfolio Analysis
13.10.2.1. Product Details, Specification, Formulation
13.10.3. Revenue, Price, and Gross Margin
13.10.4. Recent Developments and Strategies

Chapter 14. Appendix

14.1. About Us
14.2. Glossary of Terms

For questions or customization requests, please reach out to us at sales@precedenceresearch.com

Frequently Asked Questions

The global pharmaceutical manufacturing market size was valued at USD 576.54 billion in 2024 and is expected to surpass around USD 1,905.76 billion by 2034.

The pharmaceutical manufacturing market is anticipated to grow at a noteworthy CAGR of 12.7% during the forecast period 2025 to 2034.

Factors such as increasing prevalence of chronic ailments, growing geriatric population, high investment in research and development, increasing focus on outsourcing manufacturing activities, increasing per capita healthcare expenditure, growing incidence of novel viral diseases, technological advancements in manufacturing processes, and improving reimbursement scenario in developing regions are driving the growth of pharmaceutical manufacturing market.

In 2024, North America dominated the global market with a market share of more than 41%

Asia Pacific is estimated to advance at the maximum CAGR of around 15.8% in the forecast period due to high incidence of chronic ailments.

In-house drug development segment displayed the major share in the worldwide pharmaceutical manufacturing market in 2023.

The oral route of administration accounted for the largest revenue in the containers segment with more than 68% share in 2023.

The major companies operating in the worldwide pharmaceutical manufacturing market are GlaxoSmithKline plc, Merck & Co., Inc., Eli Lilly and Company, Johnson & Johnson, F. Hoffmann-La Roche Ltd., Lonza, Pfizer, Inc., Sanofi SA, Novartis AG, and AstraZeneca among others.

Proceed To Buy

USD 4900
USD 3800
USD 2100
USD 2100
USD 7500
Immediate Delivery Available

Plan your call and get expert insights!

Schedule a Meeting Schedule a Meeting

Ask For Sample

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client

down-arrow-imgGet a Sample

Connect with us now; your solution awaits on the other side!

Contact Us